[1] M. Filippi et al., “Multiple sclerosis,” Nat. Rev. Dis. Prim., vol. 4, no. 1, p. 43, 2018.
[2] D. M. Hartung, “Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA,” Neurotherapeutics, vol. 14, no. 4, pp. 1018–1026, 2017.
[3] D. L. Vargas and W. R. Tyor, “Update on disease-modifying therapies for multiple sclerosis,” Journal of Investigative Medicine, vol. 65, no. 5. pp. 883–891, 2017.
[4] S. L. Hauser et al., “B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis,” N. Engl. J. Med., vol. 358, no. 7, pp. 676–688, 2008.
[5] A. L. Greenfield and S. L. Hauser, “B-cell Therapy for Multiple Sclerosis: Entering an era,” Ann. Neurol., vol. 83, no. 1, pp. 13–26, 2018.
[6] M. A. Agius et al., “Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study,” Mult. Scler. J., pp. 1–11, 2017.
[7] B. A. C. Cree et al., “Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial,” Lancet, 2019.
[8] M. L. James et al., “Imaging B cells in a mouse model of multiple sclerosis using 64 Cu-Rituximab-PET,” J. Nucl. Med., p. jnumed.117.189597, 2017.
[9] R. H. Swanborg, “Experimental Autoimmune Encephalomyelitis,” Encycl. Immunol., pp. 856–860, Jan. 1998.
[10] M. H. J. Hagens et al., “Cerebral rituximab uptake in multiple sclerosis: A89Zr-immunoPET pilot study,” Mult. Scler. J., vol. 24, no. 4, pp. 543–545, 2018.
[11] L. Michel, H. Touil, N. B. Pikor, J. L. Gommerman, A. Prat, and A. Bar-Or, “B cells in the multiple sclerosis central nervous system: Trafficking and contribution to CNS-compartmentalized inflammation,” Front. Immunol., vol. 6, no. DEC, pp. 1–12, 2015.
[12] D. Chen, S. Gallagher, N. L. Monson, R. Herbst, and Y. Wang, “Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies.,” J. Clin. Med., vol. 5, no. 12, p. 107, Nov. 2016.
[13] O. Ilovich et al., “Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope,” Radiology, vol. 276, no. 1, pp. 191–198, 2015.
[14] H. C. Cropper et al., “Longitudinal translocator protein-18 kDa–positron emission tomography imaging of peripheral and central myeloid cells in a mouse model of complex regional pain syndrome,” Pain, vol. 160, no. 9, 2019.
[15] M. Mitsdoerffer and A. Peters, “Tertiary lymphoid organs in central nervous system autoimmunity,” Front. Immunol., vol. 7, no. OCT, pp. 1–12, 2016.
[16] A. Hoehne et al., “[(18)F]FSPG-PET reveals increased cystine/glutamate antiporter (xc-) activity in a mouse model of multiple sclerosis,” J. Neuroinflammation, vol. 15, no. 1, p. 55, Feb. 2018.
[17] M. Haugen, J. L. Frederiksen, and M. Degn, “B cell follicle-like structures in multiple sclerosis-With focus on the role of B cell activating factor,” Journal of Neuroimmunology, vol. 273, no. 1–2. Elsevier B.V., pp. 1–7, 2014.
[18] J.-A. Lyons, M. San, M. P. Happ, and A. H. Cross, “B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide,” Eur. J. Immunol., vol. 29, no. 11, pp. 3432–3439, Nov. 1999.
[19] D. K. Challa et al., “Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.,” MAbs, vol. 5, no. 5, pp. 655–9, 2013.
[20] S. Ramanathan, R. C. Dale, and F. Brilot, “Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination,” Autoimmun. Rev., vol. 15, no. 4, pp. 307–324, 2016.
[21] N. L. Monson et al., “Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis,” PLoS One, vol. 6, no. 2, pp. 1–6, 2011.
[22] J. Machado-Santos et al., “The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells,” Brain, vol. 141, no. 7, pp. 2066–2082, 2018.
[23] L. Lovato et al., “Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis,” Brain, vol. 134, no. 2, pp. 534–541, 2011.
[24] J. Barthelmes et al., “Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues,” JoVE, no. 111, p. e53933, 2016.
[25] M. Matloubian et al., “Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1,” Nature, vol. 427, no. 6972, pp. 355–360, 2004.
[26] K. P. Doyle and M. S. Buckwalter, “Does B lymphocyte-mediated autoimmunity contribute to post-stroke dementia?,” Brain. Behav. Immun., vol. 64, pp. 1–8, 2017.
[27] B. A. C. Cree et al., “Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial,” Lancet, vol. 0, no. 0.
[28] J. S. Yi, J. T. Guptill, P. Stathopoulos, R. J. Nowak, and K. C. O’Connor, “B cells in the pathophysiology of myasthenia gravis,” Muscle Nerve, vol. 57, no. 2, pp. 172–184, Feb. 2018.